|

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

RECRUITINGPhase 3Sponsored by Bristol-Myers Squibb
Actively Recruiting
PhasePhase 3
SponsorBristol-Myers Squibb
Started2026-09-08
Est. completion2031-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations37 sites

Summary

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment
* Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)
* Participants must have measurable extracranial disease per RECIST v1.1 as assessed by the investigator
* Participants must have ECOG Performance Status 0-1

Exclusion Criteria:

* Participants must not have unstable, symptomatic, or uncontrolled CNS metastases, including brain, leptomeningeal disease, and/or spinal cord compression
* Participants must not have history of ILD/pneumonitis requiring treatment with steroids (≥ Grade 2), or current or suspected ILD/pneumonitis
* Participants must not have clinically significant cardiac disease
* Other protocol-defined inclusion/exclusion criteria apply.

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Interventions5

Locations37 sites

Local Institution - 0212
Beverly Hills, California, 90211
Site 0212
Local Institution - 0504
Fullerton, California, 92835
Site 0504
Local Institution - 0357
La Jolla, California, 92093
Site 0357
Rocky Mountain Cancer Centers
Boulder, Colorado, 80304
Hossein Maymani, Site 0520000-000-0000
Local Institution - 0527
Fort Myers, Florida, 33901
Site 0527

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.